Skip to main content
UniHealth

Doctor search

Saad Munib Ahmed Khan, MD

Medical Oncology · Stanford

NPI 1083767024

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
23 years
Graduated 2003

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khan’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C164010 · Current

Licensed to practise in California · since 2019 · expires 2027-08-31 · University of the Punjab, Punjab Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Texas P3742Physician License · since 2012 · expires 2028-08-31
    ActiveNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Hematology
  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$103,641

Medicare paid this office $103,641 for 216 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)132$59,532$126
Long return visit (40+ min)42$11,369$172
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes28$9,777$105
New patient visit (60+ min)44$7,007$159
Initial hospital care with moderate level of medical decision making at least 75 minutes38$6,321$154
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)132$59,532$126
Long return visit (40+ min)42$11,369$172
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes28$9,777$105
New patient visit (60+ min)44$7,007$159
Initial hospital care with moderate level of medical decision making at least 75 minutes38$6,321$154
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's98$4,105$15
Return visit (30+ min)16$1,986$124
Return visit (30+ min)16$1,494$83
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's29$704$15

Who their Medicare patients are

216 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 9% · Women 43% · Also on Medicaid 25% · Health risk score 2.55. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 73% · Coronary heart disease 29% · Diabetes 27% · Cancer 24% · Chronic kidney disease 22% · Depression 20% · Heart failure 19% · Atrial fibrillation 19% · COPD 11% · Dementia 11% · Stroke 8%.

The office billed $283,038, Medicare allowed $132,887 and paid $103,641; for 1,086 services of 10 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242161,086732.55$283,038$103,641
2023218853742.42$224,728$103,693
2022152521742.14$157,340$58,323
2021181590732.15$154,704$62,314
2020112292733.07$94,580$28,672
2019177739733.46$243,021$74,806
2018212882732.98$288,725$93,229
2017181728723.14$213,526$70,147
2016156557712.74$164,390$51,492
2015119416703.13$132,186$31,938
2014132434702.37$138,614$35,460
2013110345682.60$114,357$28,272

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)139$64,479$131
Return visit (30+ min)96$12,910$81
New patient visit (60+ min)66$11,064$168
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$10,751$110
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,559$160
Hospital discharge day management, 30 minutes or less11$911$76

2022: 4 services

Original Medicare services billed in 2022
Long return visit (40+ min)63$19,245$125
Return visit (30+ min)71$17,373$86
New patient visit (60+ min)55$9,156$166
Initial hospital care with moderate level of medical decision making at least 75 minutes33$6,061$178

2021: 4 services

Original Medicare services billed in 2021
Return visit (30+ min)122$32,876$88
Long return visit (40+ min)68$14,954$131
New patient visit (60+ min)53$8,819$166
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,426$187

2020: 6 services

Original Medicare services billed in 2020
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a20$9,251$157
Return visit (30+ min)31$5,999$73
New patient visit (60+ min)18$2,838$158
Long return visit (40+ min)30$2,307$61
Long return visit (40+ min)11$1,781$105
Return visit (30+ min)24$1,645$53

2019: 6 services

Original Medicare services billed in 2019
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a51$36,534$157
Long return visit (40+ min)78$15,573$86
Return visit (30+ min)95$11,932$57
New patient visit (60+ min)36$4,584$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$2,817$83
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$1,449$58

2018: 7 services

Original Medicare services billed in 2018
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a58$45,158$157
Return visit (30+ min)103$15,076$61
Long return visit (40+ min)63$12,301$86
New patient visit (60+ min)54$7,268$135
Initial hospital care with moderate level of medical decision making at least 75 minutes31$4,961$160
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$4,523$82
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes27$1,920$58

2017: 8 services

Original Medicare services billed in 2017
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a38$23,050$157
Long return visit (40+ min)66$12,916$86
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes47$10,336$81
Return visit (30+ min)67$8,298$59
Initial hospital care with moderate level of medical decision making at least 75 minutes35$5,159$147
New patient visit (60+ min)33$4,301$130
Return visit (30+ min)11$1,750$58
Hospital discharge day management, 30 minutes or less12$637$53

2016: 7 services

Original Medicare services billed in 2016
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a20$13,014$157
Long return visit (40+ min)55$8,853$84
Return visit (30+ min)55$8,796$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$7,596$83
Initial hospital care with moderate level of medical decision making at least 75 minutes30$5,022$157
New patient visit (60+ min)28$3,751$134
Hospital discharge day management, more than 30 minutes14$1,193$85

2015: 6 services

Original Medicare services billed in 2015
Long return visit (40+ min)53$9,821$85
Return visit (30+ min)58$7,658$55
New patient visit (60+ min)32$4,293$134
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,041$145
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$2,761$55
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes16$2,735$80

2014: 8 services

Original Medicare services billed in 2014
Long return visit (40+ min)43$9,216$82
Return visit (30+ min)52$6,900$61
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,140$161
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$3,945$82
New patient visit (60+ min)25$3,142$126
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$2,168$57
Hospital discharge day management, more than 30 minutes17$1,526$85
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes12$1,416$109

2013: 7 services

Original Medicare services billed in 2013
Long return visit (40+ min)33$8,156$81
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,204$156
Return visit (30+ min)35$3,949$59
New patient visit (60+ min)29$3,576$123
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$3,038$78
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes19$2,325$55
Hospital discharge day management, 30 minutes or less14$786$56

Medicaid work

$7,339 in 2024

Medicaid paid $7,339 for 147 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)147$7,339
Medicaid work by year
2024147115$7,339
2023183216$7,415
202155117$1,637
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)153$6,873
Return visit (30+ min)30$542

2021

Largest Medicaid services in 2021
Return visit (30+ min)55$1,637

Drugs they prescribed that Part D paid

$1,509,955

Pharmacies billed $1,509,955 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 7% of their Part D prescriptions (19 of 272) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%.

170 generic and fewer than 11 brand-name prescriptions · $1,509,955 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Lenvima32$725,335$22,667
Retevmo15$256,994$17,133
Mekinist14$208,343$14,882
Tafinlar12$164,755$13,730
Ondansetron26$553$21
See all 8 drugs
Every Part D drug this clinician prescribed
Lenvima32$725,335$22,667
Retevmo15$256,994$17,133
Mekinist14$208,343$14,882
Tafinlar12$164,755$13,730
Ondansetron26$553$21
Levothyroxine29$282$10
Oxycodone15$159$11
Gabapentin12$99$8

Year by year

Part D prescribing by year
2024272647% (19)None$1,509,955
2023261667% (18)19%$557,153
20222094712% (26)None$505,016
2021204449% (18)36%$572,468
2020236579% (20)18%$305,069
201962210913% (79)None$789,856
20185529211% (63)None$831,832
20173576310% (34)25%$522,313
20162685820% (53)None$298,163
20153978411% (43)None$220,720
20143616014% (51)None$37,456
20133026311% (34)16%$24,111

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Ondansetron26$427$16
Levothyroxine44$367$8
Prochlorperazine Maleate15$187$12
Oxycodone13$139$11

2022: 6 drugs

Part D drugs prescribed in 2022
Mekinist13$186,335$14,333
Tafinlar13$145,420$11,186
Oxycodone20$279$14
Ondansetron17$216$13
Levothyroxine17$205$12
Prochlorperazine Maleate12$137$11

2021: 10 drugs

Part D drugs prescribed in 2021
Lenvima12$246,197$20,516
Mekinist13$175,678$13,514
Tafinlar13$132,217$10,171
Synthroid11$443$40
Oxycodone15$355$24
Ondansetron15$352$23
Levothyroxine20$318$16
Gabapentin11$173$16
Lorazepam12$66$5
Lisinopril12$33$3

2020: 7 drugs

Part D drugs prescribed in 2020
Hydrocodone-Acetaminophen16$689$43
Ondansetron34$519$15
Prochlorperazine Maleate24$279$12
Levothyroxine19$221$12
Gabapentin12$102$9
Lorazepam14$36$3
Lisinopril12$24$2

2019: 11 drugs

Part D drugs prescribed in 2019
Lenvima23$384,114$16,701
Gilotrif12$111,616$9,301
Xarelto12$5,361$447
Hydrocodone-Acetaminophen57$2,244$39
Gabapentin66$1,335$20
Ondansetron57$1,117$20
Prochlorperazine Maleate100$966$10
Nystatin13$521$40
Dexamethasone20$369$18
Levothyroxine46$268$6
Lorazepam25$104$4

2018: 13 drugs

Part D drugs prescribed in 2018
Lenvima32$446,553$13,955
Alecensa11$146,540$13,322
Xarelto21$9,693$462
Gabapentin65$1,293$20
Hydrocodone-Acetaminophen32$887$28
Ondansetron55$474$9
Nystatin15$405$27
Prochlorperazine Maleate50$321$6
Dexamethasone11$202$18
Oxycodone11$176$16
Levothyroxine24$123$5
Lorazepam19$99$5
Mirtazapine12$80$7

2017: 10 drugs

Part D drugs prescribed in 2017
Imatinib Mesylate11$109,746$9,977
Gabapentin30$632$21
Hydrocodone-Acetaminophen21$468$22
Ondansetron31$344$11
Levothyroxine26$214$8
Prochlorperazine Maleate25$156$6
Dexamethasone12$122$10
Lorazepam18$104$6
Prednisone12$85$7
Sertraline12$79$7

2016: 5 drugs

Part D drugs prescribed in 2016
Hydrocodone-Acetaminophen26$1,363$52
Ondansetron40$315$8
Gabapentin20$167$8
Prochlorperazine Maleate20$153$8
Sertraline13$70$5

2015: 11 drugs

Part D drugs prescribed in 2015
Gleevec12$120,196$10,016
Linzess11$3,108$283
Hydrocodone-Acetaminophen15$577$38
Omeprazole28$393$14
Pantoprazole15$307$20
Gabapentin16$300$19
Dexamethasone26$298$11
Ondansetron20$268$13
Gavilyte-N13$238$18
Levothyroxine24$228$9
Prochlorperazine Maleate22$123$6

2014: 9 drugs

Part D drugs prescribed in 2014
Hydrocodone-Acetaminophen17$417$25
Ondansetron33$351$11
Oxycodone12$303$25
Omeprazole28$262$9
Gavilyte-N13$245$19
Prochlorperazine Maleate33$165$5
Dexamethasone13$110$8
Citalopram Hbr22$84$4
Lorazepam14$65$5

2013: 5 drugs

Part D drugs prescribed in 2013
Omeprazole42$555$13
Hydrocodone-Acetaminophen19$356$19
Ondansetron20$285$14
Gavilyte-N12$193$16
Prochlorperazine Maleate22$115$5

Money from drug and device companies

$7,267 in 2024

Industry payments by year
2024820$5,865$7,267
2023823$41,703$42,356
2022621$74,508$74,732
2021315$63,280$63,291
20201124$54,313$54,583
20191232$18,760$19,816

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Genmab U.S.Tivdak$5,689
10 payments
  • Consulting for Tivdak · 2024-08-30 · $4,515
  • Meals for Tivdak · 2024-08-17 · $65
  • Meals for Tivdak · 2024-08-17 · $14
  • Travel for Tivdak · 2024-08-17 · $76
  • Meals for Tivdak · 2024-08-17 · $51
  • Meals for Tivdak · 2024-08-16 · $11
  • Travel for Tivdak · 2024-08-16 · $194
  • Travel for Tivdak · 2024-08-16 · $33
  • Meals for Tivdak · 2024-08-16 · $22
  • Travel for Tivdak · 2024-08-12 · $709
Coherus BiosciencesLoqtorzi$1,350
1 payment
  • Paid to speak or teach for Loqtorzi · 2024-04-30 · $1,350
AbbvieImbruvica$63
2 payments
  • Meals for Imbruvica · 2024-11-26 · $31
  • Meals for Imbruvica · 2024-01-17 · $32
Regeneron Healthcare SolutionsLibtayo$45
2 payments
  • Meals for Libtayo · 2024-07-17 · $18
  • Meals for Libtayo · 2024-06-27 · $27
Astellas Pharma USPadcev$42
2 payments
  • Meals for Padcev · 2024-05-14 · $25
  • Meals · 2024-01-09 · $16
Daiichi SankyoEnhertu$29
1 payment
  • Meals for Enhertu · 2024-11-04 · $29
See all 20 published payments
Every published payment
Janssen BiotechMeals · 2024-12-05Erleada$26
AbbvieMeals · 2024-11-26Imbruvica$31
Daiichi SankyoMeals · 2024-11-04Enhertu$29
Genmab U.S.Consulting · 2024-08-30Tivdak$4,515
Genmab U.S.Meals · 2024-08-17Tivdak$65
Genmab U.S.Meals · 2024-08-17Tivdak$14
Genmab U.S.Travel · 2024-08-17Tivdak$76
Genmab U.S.Meals · 2024-08-17Tivdak$51
Genmab U.S.Meals · 2024-08-16Tivdak$11
Genmab U.S.Travel · 2024-08-16Tivdak$194
Genmab U.S.Travel · 2024-08-16Tivdak$33
Genmab U.S.Meals · 2024-08-16Tivdak$22
Genmab U.S.Travel · 2024-08-12Tivdak$709
Regeneron Healthcare SolutionsMeals · 2024-07-17Libtayo$18
Regeneron Healthcare SolutionsMeals · 2024-06-27Libtayo$27
IncyteMeals · 2024-06-05Jakafi$23
Astellas Pharma USMeals · 2024-05-14Padcev$25
Coherus BiosciencesPaid to speak or teach · 2024-04-30Loqtorzi$1,350
AbbvieMeals · 2024-01-17Imbruvica$32
Astellas Pharma USMeals · 2024-01-09None$16
See earlier years (2023, 2022, 2021, 2020, 2019)

2023: $42,356

Payments by company in 2023
Foundation MedicineFoundationone Cdx$35,100
10 payments
  • Paid to speak or teach for Foundationone Cdx · 2023-11-08 · $4,680
  • Paid to speak or teach for Foundationone Cdx · 2023-10-04 · $4,680
  • Paid to speak or teach for Foundationone Cdx · 2023-09-12 · $2,340
  • Paid to speak or teach for Foundationone Cdx · 2023-08-25 · $2,340
  • Paid to speak or teach for Foundationone Cdx · 2023-07-19 · $4,680
  • Paid to speak or teach for Foundationone Cdx · 2023-06-07 · $2,340
  • Paid to speak or teach for Foundationone Cdx · 2023-05-17 · $4,680
  • Paid to speak or teach for Foundationone Cdx · 2023-03-31 · $4,680
  • Paid to speak or teach for Foundationone Cdx · 2023-03-08 · $2,340
  • Paid to speak or teach for Foundationone Cdx · 2023-02-14 · $2,340
Coherus BiosciencesNone$4,500
2 payments
  • Consulting · 2023-04-20 · $4,050
  • Meals · 2023-04-20 · $450
EisaiLenvima$2,573
3 payments
  • Consulting for Lenvima · 2023-12-20 · $2,173
  • Consulting for Lenvima · 2023-03-31 · $380
  • Meals for Lenvima · 2023-02-23 · $21
Astellas Pharma USXtandi$82
4 payments
  • Meals for Xtandi · 2023-12-07 · $22
  • Meals for Padcev · 2023-12-04 · $16
  • Meals for Xtandi · 2023-06-01 · $20
  • Meals for Xtandi · 2023-01-20 · $24
AmgenLumakras$27
1 payment
  • Meals for Lumakras · 2023-01-23 · $27
Genentech USALunsumio$26
1 payment
  • Meals for Lunsumio · 2023-05-22 · $26
AbbvieVenclexta$25
1 payment
  • Meals for Venclexta · 2023-01-26 · $25
Janssen BiotechErleada$23
1 payment
  • Meals for Erleada · 2023-01-16 · $23

2022: $74,732

Payments by company in 2022
Foundation MedicineFoundationone Cdx$68,983
13 payments
  • Consulting for Foundationone Cdx · 2022-12-28 · $4,680
  • Consulting for Foundationone Cdx · 2022-12-21 · $2,340
  • Consulting for Foundationone Cdx · 2022-12-13 · $878
  • Consulting for Foundationone Cdx · 2022-12-08 · $7,020
  • Consulting for Foundationone Cdx · 2022-11-16 · $4,680
  • Consulting for Foundationone Cdx · 2022-10-25 · $4,680
  • Consulting for Foundationone Cdx · 2022-09-13 · $4,680
  • Consulting for Foundationone Cdx · 2022-07-12 · $7,020
  • Consulting for Foundationone Cdx · 2022-06-14 · $4,680
  • Consulting for Foundationone Cdx · 2022-05-23 · $9,360
  • Consulting for Foundationone Cdx · 2022-04-26 · $9,945
  • Consulting for Foundationone Cdx · 2022-03-23 · $7,020
  • Consulting for Foundationone Cdx · 2022-01-11 · $2,000
EisaiLenvima$3,800
1 payment
  • Consulting for Lenvima · 2022-12-09 · $3,800
Merck KGaANone$1,725
2 payments
  • Consulting · 2022-11-30 · $1,035
  • Consulting · 2022-08-26 · $690
E.R. Squibb & Sons L.L.C.Opdivo$118
1 payment
  • Meals for Opdivo · 2022-06-08 · $118
IncyteMonjuvi$63
3 payments
  • Meals for Monjuvi · 2022-11-14 · $18
  • Meals for Pemazyre · 2022-09-27 · $20
  • Meals for Monjuvi · 2022-08-01 · $25
Coherus BiosciencesUdenyca$43
1 payment
  • Meals for Udenyca · 2022-06-04 · $43

2021: $63,291

Payments by company in 2021
Foundation MedicineFoundationone Cdx$59,125
12 payments
  • Consulting for Foundationone Cdx · 2021-12-16 · $4,000
  • Consulting for Foundationone Cdx · 2021-11-22 · $6,000
  • Consulting for Foundationone Cdx · 2021-10-29 · $4,000
  • Consulting for Foundationone Cdx · 2021-10-11 · $6,000
  • Consulting for Foundationone Cdx · 2021-09-14 · $6,000
  • Consulting for Foundationone Cdx · 2021-08-16 · $2,250
  • Consulting for Foundationone Cdx · 2021-08-09 · $4,250
  • Consulting for Foundationone Cdx · 2021-06-07 · $5,750
  • Consulting for Foundationone Cdx · 2021-05-17 · $4,500
  • Consulting for Foundationone Cdx · 2021-05-11 · $4,250
  • Consulting for Foundationone Cdx · 2021-04-26 · $4,375
  • Consulting for Foundationone Cdx · 2021-03-24 · $7,750
EisaiLenvima$4,155
2 payments
  • Consulting for Lenvima · 2021-11-11 · $2,280
  • Consulting for Lenvima · 2021-05-17 · $1,875
Merck Sharp & DohmeKeytruda$11
1 payment
  • Education for Keytruda · 2021-11-30 · $11

2020: $54,583

Payments by company in 2020
Foundation MedicineFoundationone Cdx$52,750
11 payments
  • Consulting for Foundationone Cdx · 2020-12-07 · $3,000
  • Consulting for Foundationone Cdx · 2020-11-25 · $8,250
  • Consulting for Foundationone Cdx · 2020-10-14 · $2,750
  • Consulting for Foundationone Cdx · 2020-10-14 · $7,750
  • Consulting for Foundationone Cdx · 2020-08-18 · $2,750
  • Consulting for Foundationone Cdx · 2020-08-18 · $3,000
  • Consulting for Foundationone Cdx · 2020-08-18 · $5,250
  • Consulting for Foundationone Liquid · 2020-07-06 · $5,000
  • Consulting for Foundationone Liquid · 2020-07-06 · $5,000
  • Consulting for Foundationone Liquid · 2020-05-01 · $5,250
  • Consulting for Foundationone Liquid · 2020-03-20 · $4,750
EisaiLenvima$1,587
2 payments
  • Consulting for Lenvima · 2020-10-26 · $1,563
  • Meals for Lenvima · 2020-09-15 · $24
Eli Lilly andNone$52
1 payment
  • Travel · 2020-02-03 · $52
BiotronikNone$46
1 payment
  • Meals · 2020-03-03 · $46
Merck Sharp & DohmeKeytruda$27
2 payments
  • Meals for Keytruda · 2020-03-06 · $14
  • Meals for Keytruda · 2020-03-02 · $13
AmgenNplate$27
1 payment
  • Meals for Nplate · 2020-03-03 · $27
Lilly USAVerzenio$26
2 payments
  • Meals for Verzenio · 2020-01-24 · $13
  • Meals for Verzenio · 2020-01-08 · $13
Novartis PharmaceuticalsPiqray$22
1 payment
  • Meals for Piqray · 2020-03-03 · $22
Alexion PharmaceuticalsUltomiris$18
1 payment
  • Meals for Ultomiris · 2020-03-05 · $18
Janssen BiotechErleada$15
1 payment
  • Meals for Erleada · 2020-02-03 · $15
IncyteJakafi$14
1 payment
  • Meals for Jakafi · 2020-02-21 · $14

2019: $19,816

Payments by company in 2019
Foundation MedicineFoundationone Liquid$15,050
7 payments
  • Consulting for Foundationone Liquid · 2019-11-22 · $2,000
  • Consulting for Foundationone Liquid · 2019-11-22 · $2,000
  • Consulting for Foundationone Liquid · 2019-10-17 · $2,250
  • Consulting for Foundationone Liquid · 2019-09-24 · $1,750
  • Consulting for Foundationone Liquid · 2019-06-27 · $4,250
  • Consulting for Foundationone Liquid · 2019-05-23 · $1,600
  • Consulting for Foundationone Liquid · 2019-01-11 · $1,200
GenentechTecentriq$4,432
5 payments
  • Travel for Tecentriq · 2019-10-12 · $348
  • Consulting for Tecentriq · 2019-10-12 · $3,710
  • Travel for Tecentriq · 2019-10-12 · $133
  • Meals for Tecentriq · 2019-10-12 · $54
  • Meals for Tecentriq · 2019-10-12 · $187
EisaiLenvima$63
3 payments
  • Meals for Lenvima · 2019-09-13 · $22
  • Meals for Lenvima · 2019-07-24 · $18
  • Meals for Lenvima · 2019-04-09 · $23
Merck Sharp & DohmeLynparza$57
5 payments
  • Meals for Lynparza · 2019-10-07 · $13
  • Meals for Lynparza · 2019-09-12 · $11
  • Meals for Keytruda · 2019-08-21 · $14
  • Meals for Lynparza · 2019-06-12 · $13
  • Meals for Keytruda · 2019-03-21 · $5
Mylan InstitutionalFulphila$44
2 payments
  • Meals for Fulphila · 2019-11-04 · $23
  • Meals for Fulphila · 2019-06-14 · $20
IncyteJakafi$33
2 payments
  • Meals for Jakafi · 2019-08-01 · $21
  • Meals for Jakafi · 2019-06-11 · $12
Lilly USAVerzenio$31
2 payments
  • Meals for Alimta · 2019-08-29 · $14
  • Meals for Verzenio · 2019-02-11 · $17
AstraZeneca Pharmaceuticals LPCalquence$30
2 payments
  • Meals for Calquence · 2019-09-17 · $18
  • Meals for Lynparza · 2019-06-21 · $12
AmgenKyprolis$22
1 payment
  • Meals for Kyprolis · 2019-08-08 · $22
AbbVieVenclexta$21
1 payment
  • Meals for Venclexta · 2019-11-07 · $21
Seattle GeneticsAdcetris$19
1 payment
  • Meals for Adcetris · 2019-04-22 · $19
Pharmacyclics LLC An AbbVieImbruvica$15
1 payment
  • Meals for Imbruvica · 2019-08-19 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2023Their institution$428,662
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2019Their institution$392,915
PFIZER INC. · A Phase 1b2 Openlabel Study To Evaluate Safety Clinical Activity Pharmacokinetics and Pharmacodynamics of Avelumab Msb0010718c in Combination With Other Cancer Immunotherapies in Patients With Advanced Malignancies · 2019Their institution$261,205
Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2022Their institution$235,296
Merck Sharp & Dohme LLC · Study Name#Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplastic,Undifferentiated Thyroid Cancer · 2024Their institution$157,056
Merck Sharp & Dohme LLC · Study Name#Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplastic,Undifferentiated Thyroid Cancer · 2025Their institution$140,158
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2020Their institution$136,066
Genentech, Inc. · A Phase Ia Ib Open Label Dose Escalation Study of the Safety and Pharmacokinetics of Xmab24306 Alo · 2024Their institution$115,900
Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2021Their institution$111,783
Genentech, Inc. · A Phase Ia Ib Open Label Dose Escalation Study of the Safety and Pharmacokinetics of Xmab24306 Alo · 2025Their institution$108,436
Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2019Their institution$81,985
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2019Their institution$62,482
AbbVie, Inc. · 2019Their institution$61,336
BeOne Medicines USA, Inc. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025Their institution$58,211
BeiGene, Ltd. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2024Their institution$52,040
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2020Their institution$43,920
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (La Hnscc) · 2019Their institution$43,323
BeiGene, Ltd. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025Their institution$38,248
BeiGene USA, Inc. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025Their institution$28,370
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2020Their institution$26,599
Ascendis Pharma, Inc. · A Study of Transcon Tlr7/8 Agonist With Or Without Pembrolizumab in Patients With Advanced Or Metastatic Solid Tumors · 2022Their institution$25,286
Ascendis Pharma Inc · Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon Tlr7/8 Agonist Alone Or in Combination With Pembrolizumab in Participants With Locally Advanced Or Metastatic Solid Tumor Malignancies · 2023Their institution$24,320
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2019Their institution$24,306
AbbVie Inc. · 2020Their institution$21,701
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With Or Without Pembrolizumab (Mk-3475) in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) Participants (Keynote-789) · 2019Their institution$21,662
Merck Sharp & Dohme Corporation · A Phase 3 Clinical Trial of Pembrolizumab Mk-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma · 2019Their institution$16,851
Bayer HealthCare Pharmaceuticals Inc. · Clinical Trial Pase IV (Post Marketing) (Bayer Product Or Ta) · 2020Their institution$10,894
Bayer HealthCare Pharmaceuticals Inc. · Bay2757556, Open Label Basket Trial · 2022Their institution$6,067
Bayer HealthCare Pharmaceuticals Inc. · Clinical Trial Pase IV (Post Marketing) (Bayer Product Or Ta) · 2019Their institution$4,062
Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025Their institution$2,837

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1083767024
Licence
CA C164010, TX P3742California C164010: Current · expires 2027-08-31Texas P3742: Active
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-01-22
NPI last updated
2024-04-25
NPI record certified
2024-04-25

This is when the NPI record was last certified, not a medical board exam.